All In Biotech

Drug Trial Radar · NCT04145258

Intensified Tuberculosis Treatment to Reduce the Mortality of Patients With Tuberculous Meningitis

Intensified Tuberculosis Treatment to Reduce the Mortality of HIV-infected and Uninfected Patients With Tuberculosis Meningitis: a Phase III Randomized Controlled Trial (Acronym: INTENSE-TBM)

Last checked: Nov 20, 2026Latest source record: Jun 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 768 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

768

Planned (sponsor's estimate)

Start

Feb 7, 2021

Primary completion

Sep 23, 2026

Study completion Sep 26, 2026

Sponsor

Lead sponsor
ANRS, Emerging Infectious DiseasesGovernment (non-federal)
Sponsor type
Government (non-federal)
Collaborators
European Union; European and Developing Countries Clinical Trials Partnership (EDCTP)
First posted
Oct 30, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Factorial
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 15 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

INTENSE-TBM is randomized controlled, phase III, multicenter, 2 x 2 factorial plan superiority trial assessing the efficacity of two interventions to reduce mortality from tuberculous meningitis (TBM) in adolescents and adults with or without HIV-infection in sub-Saharan Africa: * Intensified TBM treatment with high-dose rifampicin and linezolid, compared to WHO standard TBM treatment. * Aspirin, compared to not receiving aspirin. The trial will be open-label for anti-TB treatment and placebo-controlled for aspirin treatment.

Conditions

  • Tuberculous Meningitis

Interventions

  • AspirinDrug

    Two tablets of aspirin 100 mg per day from inclusion (D-0) to end of Week-8 (W-8)

  • Placebo of aspirinDrug

    Two placebo tablets with the same appearance of aspirin 100 mg per day from inclusion (D-0) to end of Week-8 (W-8)

  • WHO TBM treatmentDrug

    2 months of (R-H-Z-E) + 7 months of (R-H)

  • Intensified TBM treatmentDrug

    2 months of (HDR-L-H-Z-E) + 7 months of (R-H), with HDR=high-dose rifampicin and L=linezolid

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of all-cause deathTime frame: Up to 40 weeks

Locations

13 sites in 4 countries. Site status is shown where the registry gives one.

  • Cocody University Hospital

    Abidjan, Côte d’Ivoire · Not yet recruiting

  • Treichville University Hospital

    Abidjan, Côte d’Ivoire · Recruiting

  • Yopougon University Hospital

    Abidjan, Côte d’Ivoire · Not yet recruiting

  • University Hospital Joseph Raseta Befelatanana

    Antananarivo, Madagascar · Recruiting

  • University Hospital Tambohobe

    Fianarantsoa, Madagascar · Recruiting

  • Morafeno University Hospital

    Toamasina, Madagascar · Not yet recruiting

  • Kayelitsha District Hospital

    Cape Town, South Africa · Recruiting

  • Mitchells Plain Hospital

    Cape Town, South Africa · Recruiting

  • New Somerset Hospital

    Cape Town, South Africa · Recruiting

  • Dora Nginza Hospital

    Port Elizabeth, South Africa · Recruiting

  • Livingstone and PE Central Hospitals

    Port Elizabeth, South Africa · Recruiting

  • Mbarara Regional Reference Hospital

    Mbarara, Uganda · Recruiting

  • Regional Reference Hospital of Kabale

    Mbarara, Uganda · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.